Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 2
2002 3
2003 2
2004 5
2005 4
2006 2
2007 2
2008 2
2009 2
2011 3
2012 3
2013 5
2014 5
2015 6
2016 4
2017 3
2018 3
2019 13
2020 16
2021 13
2022 6
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. Horwitz S, et al. Among authors: domingo domenech e. Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16. Ann Oncol. 2022. PMID: 34921960 Free PMC article. Clinical Trial.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Among authors: domingo domenech e. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Trümper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Savage KJ, et al. Among authors: domingo domenech e. Blood Adv. 2022 Oct 11;6(19):5550-5555. doi: 10.1182/bloodadvances.2020003971. Blood Adv. 2022. PMID: 35470385 Free PMC article. Clinical Trial.
Unraveling the genetics of transformed splenic marginal zone lymphoma.
Grau M, López C, Navarro A, Frigola G, Nadeu F, Clot G, Bastidas-Mora G, Alcoceba M, Baptista MJ, Blanes M, Colomer D, Costa D, Domingo-Domènech E, Enjuanes A, Escoda L, Forcada P, Giné E, Lopez-Guerra M, Ramón O, Rivas-Delgado A, Vicente Folch L, Wotherspoon A, Climent F, Campo E, López-Guillermo A, Matutes E, Beà S. Grau M, et al. Among authors: domingo domenech e. Blood Adv. 2023 Jul 25;7(14):3695-3709. doi: 10.1182/bloodadvances.2022009415. Blood Adv. 2023. PMID: 36995085 Free PMC article.
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martín García-Sancho A, Rodríguez-Pinilla SM, Domingo-Domenech E, Climent F, Sánchez-Garcia J, López Jiménez J, García-Cosío Piqueras M, Castellvi J, González AJ, González de Villambrosia S, Gómez Codina J, Navarro B, Rodríguez G, Borrero JJ, Fraga M, Naves A, Baeza L, Córdoba R. Martín García-Sancho A, et al. Among authors: domingo domenech e. Br J Haematol. 2023 Oct;203(2):182-193. doi: 10.1111/bjh.18941. Epub 2023 Jun 30. Br J Haematol. 2023. PMID: 37386897
Brentuximab vedotin for lymphoma in paediatric patients.
Sureda A, Domingo-Domènech E. Sureda A, et al. Among authors: domingo domenech e. Lancet Haematol. 2018 Oct;5(10):e433-e434. doi: 10.1016/S2352-3026(18)30160-1. Lancet Haematol. 2018. PMID: 30290898 No abstract available.
94 results